等待开盘 05-19 09:30:00 美东时间
-0.310
-0.71%
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI,
05-14 20:40
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从9美元升至11美元;康托·菲茨杰拉德:维持Artiva Biotherapeutics"超配"评级,目标价从10美元升至40美元
05-12 12:36
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
今日重点评级关注:Citizens:维持Avalo Therapeutics"跑赢大市"评级,目标价从52美元升至62美元;BTIG:维持Avalo Therapeutics"买入"评级,目标价从40美元升至58美元
05-07 12:37
TD Cowen analyst Dan Brennan maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $65 to $68.
05-07 02:28
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.
05-06 18:12
华盛资讯5月6日讯,Tempus Al公布2026财年Q1业绩,公司Q1营收3.48亿美元,同比增长36.1%,归母净利润亏损1.26亿美元,同比亏损扩大85.1%。
05-06 10:34
Tempus AI shares are trading lower, The company reported Q1 financial results.
05-06 05:06
华盛资讯5月6日讯,Tempus Al公布2026财年Q1业绩,公司Q1营收3.48亿美元,同比增长36.1%,归母净利润亏损1.26亿美元,同比亏损扩大85.1%。
05-06 07:32
Tempus AI (NASDAQ:TEM) raises FY2026 sales outlook from $1.590 billion to $1.590 billion-$1.600 billion vs $1.592 billion estimate.
05-06 04:04